Hepatitis C Worsens Outcomes in Patients Who Abuse Alcohol

The interaction between alcohol abuse and hepatitis C virus (HCV) can compromise overall survival outcomes, according to a study published in Clinical Epidemiology.
 
Between 10% and 20% of individuals who consume alcohol excessively develop alcoholic liver disease, according to the researchers. The study noted that approximately 20% of patients with alcoholic hepatitis have HCV. Notably, rates of liver-related mortality grew worldwide from 2005 to 2015, which reflects changes in risk factors such as excessive alcohol consumption and HCV infection, according to the study.
 
HCV infection is a significant risk factor for liver disease progression and related deaths due to conditions such as cirrhosis and hepatocellular cancer. Furthermore, individuals with HCV are more likely to consume alcohol than those without the virus, which may point to a link between poor outcomes and mortality from liver-related conditions, according to the study.
 
To evaluate the association, the researchers conducted a longitudinal study of 819 patients treated for alcohol abuse between 2000 and 2010. The authors collected data at entry into the study on alcohol use characteristics, alcoholic liver disease, and HCV infection.
 
Of the patients in the study, 15.8% were infected with HCV. There were 129 all-patient deaths over 5117 person-years during a median follow-up of 6.4 years, with 31 (24.6%) deaths among patients with HCV and 98 (15.4%) among HCV-negative patients.
 
The duration of survival among patients with HCV was 34% shorter than those who did not have the virus, while liver-related mortality was significantly higher among patients with HCV. Of the 129 patient deaths during the study, 48.4% were attributed to liver-related mortality, 22.4% were related to neoplasia, 11.6% were a result of nonnatural death, and 9.3% were due to cardiovascular disease.
 
The authors of the current study pointed to prior research that found up to 30% of patients with HCV may abuse alcohol. They also noted that liver-related mortality is 6-times greater in HCV-positive patients compared with HCV-negative patients with liver-related complications.
 
The current study’s limitations included a lack of data on changes in alcohol consumption over time and a lack of data on individuals with less severe patterns of alcohol consumption, which the authors said limited the generalization of results.
 
“Alcohol abuse/dependence and HCV infection are conditions that may have clinical consequences when interacting,” the authors concluded. “In summary, hepatitis C worsens the prognosis of liver disease and compromises the survival of alcohol-dependent patients. In this sense, treatment and care of HCV infection may result in better clinical outcomes in these patients.”


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.
Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.
Study investigates whether direct-acting antiviral drugs for hepatitis C virus increase the risk of developing hepatocellular carcinoma.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$